Product Description
For Paroxysmal Nocturnal Hemoglobinuria (PNH) (Sourced from: https://clinicaltrials.gov/ct2/show/study/NCT03225287?term=NCT03225287&rank=1)
Mechanisms of Action: C5 Inhibitor
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Subcutaneous
FDA Designation: *
Approval Status: Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: UCB
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Canada, France, Germany, Italy, Japan, Korea, Netherlands, Norway, Poland, Spain, United Kingdom, United States
Active Clinical Trial Count: 14
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Muscle Weakness|Myasthenia Gravis
Phase 1: Healthy Volunteers
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT04225871 |
RAISE-XT | P3 |
Active, not recruiting |
Muscle Weakness|Myasthenia Gravis |
2026-06-02 |
27% |
2024-06-04 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
NCT06511076 |
DV0012 | P1 |
Completed |
Healthy Volunteers |
2024-11-26 |
50% |
2024-12-07 |
Primary Completion Date|Primary Endpoints|Study Completion Date |
JapicCTI-205225 |
JapicCTI-205225 | P3 |
Planned |
Myasthenia Gravis |
2022-12-31 |
|||
2022-502073-42-00 |
MG0015 | P3 |
Not yet recruiting |
Myasthenia Gravis |
2027-12-06 |
25% |
2025-05-02 |
Treatments |
NCT06435312 |
ziMyG+ | P3 |
Enrolling by invitation |
Muscle Weakness|Myasthenia Gravis |
2027-10-26 |
25% |
2024-12-04 |
|
2022-502072-23-00 |
MG0014 | P3 |
Not yet recruiting |
Myasthenia Gravis |
2026-12-04 |
25% |
2025-05-02 |
Treatments |
NCT06055959 |
ziMyG | P3 |
Recruiting |
Muscle Weakness|Myasthenia Gravis |
2026-11-16 |
25% |
2024-08-16 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments |
2024-512399-37-00 |
RA101495-02.302 | P3 |
Active, not recruiting |
Myasthenia Gravis |
2026-05-20 |
2025-05-02 |
Treatments |
|
NCT06471361 |
DV0013 | P3 |
Completed |
Muscle Weakness|Myasthenia Gravis |
2025-01-28 |
40% |
2025-02-19 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
2023-508287-30-00 |
DV0013 | P3 |
Completed |
Myasthenia Gravis |
2024-09-30 |
2025-05-02 |
Treatments |
|
jRCT2080225129 |
jRCT2080225129 | P3 |
Completed |
Myasthenia Gravis |
2024-08-31 |
|||
NCT05514873 |
MG0017 | P3 |
Completed |
Myasthenia Gravis|Muscle Weakness |
2024-03-13 |
43% |
2024-11-01 |
Primary Endpoints |
NCT06961747 |
UP0137 | P1 |
Recruiting |
Healthy Volunteers |
2026-07-22 |
88% |
2025-08-13 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
JapicCTI-205226 |
JapicCTI-205226 | P3 |
Active |
Myasthenia Gravis |
2021-04-30 |